Table 3.

Early- and Late-Stage Cancer Rates for Current- and Future-State Scenarios^a

	Commercially insured incidence rates
	Premenopausal women			Postmenopausal women
Cancer stage	Current state, %	Future state, %b	Change, %	Current state, %	Future state, %b	Change, %
Early-stage	37.50	40.77	3.27	26.60	26.98	0.38
Late-stage	62.50	59.23	−3.27	73.40	73.02	−0.38

	Medicare incidence rates
	Premenopausal womenc			Postmenopausal women
Cancer stage	Current state, %	Future state, %	Change, %	Current state, %	Future state, %b	Change, %
Early-stage	N/A	N/A	N/A	26.60	26.98	0.38
Late-stage	N/A	N/A	N/A	73.40	73.02	−0.38

^aModel assumes 20% OVA1 penetration rate.

^bModel assumes that 50% of early-stage cancers are misdiagnosed by CA125 test.10

^cModel assumes all Medicare cases are postmenopausal.

N/A indicates not applicable.